Loading
A phase 1/2 trial of BIO-106, Pembrolizumab in metastatic cancer, run by BiOneCure Therapeutics Inc., now recruiting.
A Study in Patients With Advanced Cancers is a phase 1/2 interventional study registered as NCT05320588 by BiOneCure Therapeutics Inc., with 332 participants planned, started 2022-03-25 and due to reach its primary completion in 2024-04. Interventions recorded: BIO-106, Pembrolizumab. Conditions listed: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology. No results are recorded here; the registry entry is the source.
Shares BIO-106, Antibody-drug conjugate (ADC).